Risk Factors Update Summary
- Added Evolve to commercialization dependence, now authorized to sell in 30 states.
- Added Evolve to products available for commercialization, may impact profitability if unsuccessful.
- Added factors affecting success of ContraPest and Evolve, including market acceptance and manufacturing processes.
- Added geopolitical instability risks due to Russia-Ukraine conflict and Israel-Hamas wars.
- Decrease in full-time employees from 29 to 25, potential impact on operations.
- Reverse stock split approved from 1-for-5 to 1-for-12, affecting liquidity and odd lot shareholders.
- Reverse stock splits may increase difficulty in selling odd lots of shares.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1680378&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.